Most frequently recorded adverse events during polatuzumab vedotin treatment
| . | Salvage cohort (n = 52)* . | Bridging cohort (n = 49)* . | ||
|---|---|---|---|---|
| Adverse event . | All grades (%) . | Grades 3-4 (%) . | All grades (%) . | Grades 3-4 (%) . |
| Blood disorders | ||||
| Anemia | 41 (78.8) | 14 (26.9) | 35 (71.4) | 14 (28.6) |
| Thrombocytopenia | 33 (63.5) | 17 (32.7) | 25 (51.0) | 10 (20.4) |
| Neutropenia | 31 (59.6) | 20 (38.5) | 17 (34.7) | 12 (24.5) |
| Febrile neutropenia | 12 (23.1) | 8 (15.4) | 3 (6.1) | 3 (6.1) |
| Infections† | 20 (38.5) | 10 (19.2) | 14 (28.6) | 11 (22.4) |
| Polyneuropathy | 11 (21.2) | 0 | 7 (14.3) | 0 |
| Tumor lysis | 2 (3.8) | 2 (3.8) | 4 (8.2) | 4 (8.2) |
| . | Salvage cohort (n = 52)* . | Bridging cohort (n = 49)* . | ||
|---|---|---|---|---|
| Adverse event . | All grades (%) . | Grades 3-4 (%) . | All grades (%) . | Grades 3-4 (%) . |
| Blood disorders | ||||
| Anemia | 41 (78.8) | 14 (26.9) | 35 (71.4) | 14 (28.6) |
| Thrombocytopenia | 33 (63.5) | 17 (32.7) | 25 (51.0) | 10 (20.4) |
| Neutropenia | 31 (59.6) | 20 (38.5) | 17 (34.7) | 12 (24.5) |
| Febrile neutropenia | 12 (23.1) | 8 (15.4) | 3 (6.1) | 3 (6.1) |
| Infections† | 20 (38.5) | 10 (19.2) | 14 (28.6) | 11 (22.4) |
| Polyneuropathy | 11 (21.2) | 0 | 7 (14.3) | 0 |
| Tumor lysis | 2 (3.8) | 2 (3.8) | 4 (8.2) | 4 (8.2) |